Literature DB >> 9006503

Herpes simplex virus antibodies in the perilymph of patients with Menière disease.

W Arnold1, H P Niedermeyer.   

Abstract

OBJECTIVE: To evaluate the presence of IgG antibodies directed to herpes simplex virus (HSV) in the perilymph of patients with Menière disease.
DESIGN: Antibodies to HSV, Epstein-Barr virus, cytomegalovirus, and measles virus were analyzed in serum and perilymph samples by enzyme-linked immunosorbent assay. Total IgG and albumin in serum and perilymph samples were measured by nephelometer analysis. The relation of specific antivirus IgG in the perilymph vs the serum was expressed as an index. PATIENTS: Perilymph and serum samples from 7 patients with long-standing, disabling Menière disease were collected during therapeutic vestibulotomy. Perilymph and serum samples from 7 patients with otosclerosis and 2 recipients of cochlear implants were used as controls.
RESULTS: Compared with the corresponding serum sample, the perilymph from the patients with Menière disease disclosed a higher level of specific anti-HSV IgG. An elevated level of specific anti-measles virus IgG in the perilymph was detected in patients with otosclerosis. Patients of all groups showed no variation of specific anti-Epstein Barr virus IgG and anti-cytomegalovirus IgG in the serum or in the perilymph.
CONCLUSIONS: Our results show the presence of HSV IgG in the perilymph of patients with Menière disease and support the hypothesis that HSV may play an important role in the etiopathogenesis of Menière disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9006503     DOI: 10.1001/archotol.1997.01900010061008

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  10 in total

1.  No evidence of measles virus in stapes samples from patients with otosclerosis.

Authors:  A B Grayeli; P Palmer; P Tran Ba Huy; J Soudant; O Sterkers; P Lebon; E Ferrary
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

2.  Intratympanic dexamethasone injections for refractory Meniere' s disease.

Authors:  Hongmiao Ren; Tuanfang Yin; Yongde Lu; Weijia Kong; Jihao Ren
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 3.  The Price of Immune Responses and the Role of Vitamin D in the Inner Ear.

Authors:  Béla Büki; Heinz Jünger; Yan Zhang; Yunxia Wang Lundberg
Journal:  Otol Neurotol       Date:  2019-07       Impact factor: 2.311

4.  Incidence of virus infection as a cause of Meniere's disease or endolymphatic hydrops assessed by electrocochleography.

Authors:  Ziane Selmani; Timo Marttila; Ilmari Pyykkö
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-07-02       Impact factor: 2.503

5.  Procedures for restoring vestibular disorders.

Authors:  Leif Erik Walther
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

6.  The role of cyclooxygenase in multiplication and reactivation of HSV-1 in vestibular ganglion neurons.

Authors:  Yuehong Liu; Shufeng Li; Zhengmin Wang
Journal:  ScientificWorldJournal       Date:  2014-02-05

Review 7.  The aetiopathologies of Ménière's disease: a contemporary review.

Authors:  B S Oberman; V A Patel; S Cureoglu; H Isildak
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-08       Impact factor: 2.124

8.  Association between Meniere's disease and air pollution in South Korea.

Authors:  Dong-Han Lee; Jiyeon Han; Myoung-Jin Jang; Myung-Whan Suh; Jun Ho Lee; Seung Ha Oh; Moo Kyun Park
Journal:  Sci Rep       Date:  2021-06-23       Impact factor: 4.379

Review 9.  Viral causes of hearing loss: a review for hearing health professionals.

Authors:  Brandon E Cohen; Anne Durstenfeld; Pamela C Roehm
Journal:  Trends Hear       Date:  2014-07-29       Impact factor: 3.293

10.  Are viral-infections associated with Ménière's Disease? A systematic review and meta-analysis of molecular-markers of viral-infection in case-controlled observational studies of MD.

Authors:  Nicholas John Dean; Christopher Pastras; Daniel Brown; Aaron Camp
Journal:  PLoS One       Date:  2019-11-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.